Glaucoma surgery that when combined with cataract surgery, the IOP is reduced even further than when done alone. Long term (three year) results have been published both in the US and Europe demonstrating a significant and sustained reduction in both eye pressure and the number of glaucoma medications required for glaucoma control. Certain cells within the eye's ciliary body produce aqueous humor. A ciliary destructive or cyclodestructive procedure is one that aims to destroy those cells in order to reduce intraocular pressure. Cyclocryotherapy, or cyclocryopexy, uses a freezing probe. Cyclophotocoagulation, also known as transscleral cyclophotocoagulation, ciliary body ablation, cyclophotoablation, and cyclophototherapy, uses
Minimally invasive glaucoma surgery vision and take extra time to recover. The surgery site can scar over time and the pressure can go back up. In early 2014, the NeoMedix received a warning letter from FDA regarding marketing practices. Minimally invasive glaucoma surgery Micro-invasive glaucoma surgery (MIGS) is the latest advance in surgical treatment for glaucoma, which aims to reduce intraocular pressure by either increasing outflow of aqueous humor or reducing its production. MIGS comprises a group of surgical procedures which share common features. MIGS procedures involve a minimally invasive approach, often with small cuts or micro-incisions through the cornea that causes the least